With replacement shelved, regulations could decide ACA’s fate

John Gregory | | Health Exec | Policy & Regulations

The Republican-controlled House couldn’t pass a replacement for the Affordable Care Act, but if the goal is to weaken the law, the executive branch can do so all on its own.

As explained by Reuters, HHS Secretary Tom Price can roll back many of the underlying ACA regulations. He’s already done so on other healthcare polices, like delaying the start of mandatory bundled payment models finalized in the last days of the Obama administration.

If Price uses his administrative powers to target the ACA or the Medicare Access and CHIP Reauthorization Act (MACRA), both insurance market stability and the transition to value-based care could be affected.

Read the full article below: 

How Republicans can hobble Obamacare even without repeal

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
Kentucky AG launches criminal probe after conscious man nearly has organs harvested
FDA announces Class I recall of ventilators after 3 patient injuries
FDA clears AI tool that flags signs of heart disease in chest CT scans
Stewardship Health sale to private equity finalized for $245M
Baxter producing IV solutions ahead of schedule at Asheville-area site

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup